SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Rapyd raises $500M at $4.5B valuation to complete $610M PayU acquisition

Where will US markets find their bottom? A model points to a potential 11% drop

Matrix looks to Wall Street: $2.1 billion merger could pave way for Nasdaq listing

IAI reports record $6.1 billion in sales as global demand for weapons surges

Buzz

Most popular

Daily

Weekly

1

Rapyd raises $500M at $4.5B valuation to complete $610M PayU acquisition

2

"Eventually, AI will surpass us in everything"—so what skills will still matter?

3

Cyber unicorn Pentera raises $60M at over $1B valuation as ARR approaches $100M

4

Sola Security aims to be the Wix of cyber with $30 million Seed round

5

Cyber startup ActiveFence cuts 7% of workforce

BioProtect

3 stories about BioProtect

Itay Barnea BioProtect

Is it time to reconsider PSA tests for Prostate Cancer?

01.09.22|Itay Barnea

“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea, CEO of BioProtect

חולה קורונה אשפוז בית חולים רופאים ג'נבה ז'נווה שוויץ

Which Israeli cancer treatment company raised $57 million and who is making money off double chins?

CTech Daily Roundup: Medtronic invests $4.5 million as part of BioProtect $25 million series D

מוסף ניתוח מנתח מנתחים רופא רופאים

Medtronic invests $4.5 million as part of BioProtect $25 million series D

22.09.20|Meir Orbach

Proceeds of the round will finance the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy